← Leaderboards
Cornelis P Vlaar
University Of Puerto Rico Med Sciences
$748,000
Attributed
$748,000
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $149K · FY2016–25$200K$150K$100K$50K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$748,000 · 2
By mechanism
SC3$450,000 · 1
R16$298,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventNovel TherapeuticsMigrationMalignant NeoplasmsMolecularNeoplasm MetastasisIn VivoGuanosine Triphosphate PhosphohydrolasesCessation Of LifeLeadDisseminated Malignant NeoplasmDesignBindingDockingBiochemical ProcessCancer TherapyFamilyGuanine Nucleotide Exchange FactorsCell MotilityCancer CellLaboratoriesCancer EtiologyComplexPrimary Neoplasm
Grant awards (6)
Assessment of small molecules as covalent inhibitors of Rac/Cdc42$149,000
R16 · FY2025 · GM · contact PI
Assessment of small molecules as covalent inhibitors of Rac/Cdc42$149,000
R16 · FY2024 · GM · contact PI
Towards the Development of Novel Vav-Rac Inhibitors$112,500
SC3 · FY2019 · GM · contact PI
Towards the Development of Novel Vav-Rac Inhibitors$112,500
SC3 · FY2018 · GM · contact PI
Towards the Development of Novel Vav-Rac Inhibitors$112,500
SC3 · FY2017 · GM · contact PI
Towards the Development of Novel Vav-Rac Inhibitors$112,500
SC3 · FY2016 · GM · contact PI